To further demonstrate these two HSP70 inhibitors in clinical applications, conditionally reprogrammed cells (CRCs) were established from a Gleason 10 score prostate cancer patient based on the published protocol 30. This evidence concerns the gene HSPA1A and Familial prostate cancer.